Melatonin CR

Phase 1Small molecule

NNational Human Genome Research Institute (NHGRI)

Melatonin CR is one of 3 small molecule programs targeting Smith-Magenis syndrome. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Smith-Magenis SyndromeActive, not recruiting

Smith-Magenis SyndromePhase 1

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Smith-Magenis Syndrome

#DrugCompanyPhaseTrials

Hetlioz

VVanda Pharmaceuticals

Approved

—2

Circadin

NNeurim Pharmaceuticals Ltd.

Preclinical

—3

Melatonin CR

NNational Human Genome Research Institute (NHGRI)

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Smith-Magenis syndrome1 trial

Treatment Strategies for Children With Smith-Magenis Syndrome

Completed·NNational Human Genome Research Institute (NHGRI)·Phase 1·NCT00506259·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Melatonin CR. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Melatonin CR compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Melatonin CR. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Human Genome Research Institute (NHGRI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNational Human Genome Research Institute (NHGRI)

Melatonin CR

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Smith-Magenis syndrome1 trial

References

Drug Info

Quick Facts

Related News